The efficacy and safety of long-acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA) in COPD patients with benign prostatic hyperplasia (BPH)
Not Applicable
Completed
- Conditions
- Chronic obstructive pulmonary disease (COPD)
- Registration Number
- JPRN-UMIN000009357
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
History of hyper-sensitivity to long-acting muscarinic antagonist (LAMA), long-acting beta2-agonist (LABA), inhaled corticosteroid (ICS) Patients with bronchial asthma Patients during acute exacerbation Presence of infectious disease, pneumothorax, and severe heart failure
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method